Wedgewood recalls compounded veterinary drugs over potency concerns

Wedgewood Pharmacy has launched a nationwide voluntary recall of certain compounded veterinary medications within expiry after identifying inconsistencies in analytical testing data generated by its laboratory, raising the possibility that some products may be subpotent or superpotent. FDA published the company’s announcement on October 21, 2026, and the affected products were shipped from February 18 through October 6, 2026, to veterinary practices, pharmacies, and other customers across the U.S. The company said it has received 98 complaints to date, including seven considered serious. (fda.gov)

The recall lands in a part of veterinary medicine where clinicians often have few easy substitutes. Compounded medications are routinely used when no FDA-approved product can safely or practically meet a patient’s needs, including when a species-specific strength, dosage form, concentration, or excipient profile is required. At the same time, experts in veterinary pharmacy have emphasized that compounded products are not FDA-approved and do not come with the same assurance of consistent manufacturing, proven stability, and release testing that applies to approved drugs. (todaysveterinarypractice.com)

According to FDA’s recall notice, the products span powders, pastes, oral suspensions, injectables, ophthalmic ointments and solutions, ear solutions and suspensions, topical sprays, and gels. They were intended for companion, equine, exotic, zoo, wildlife, and aquatic animals, but not for food-producing animals. Wedgewood said the problem was detected through its own quality processes and stems from data reliability concerns rather than a publicly described contamination event or a single named ingredient. The company has posted a recall lookup tool and says Sedgwick is handling recall coordination, refunds, and, where possible, replacement products. (fda.gov)

Wedgewood’s public messaging has focused on continuity of care. The company says veterinarians and pet parents with affected products should stop use, retain the medication, and contact recall support, while prescribers should make individual treatment decisions based on the patient and available alternatives. That matters because a potency failure can cut both ways: low-potency products may lead to undertreatment or apparent therapeutic failure, while high-potency products can increase the risk of toxicity or overdose. (fda.gov)

Broader regulatory context makes the recall notable. FDA’s current framework for animal compounding under GFI #256 recognizes that compounded preparations can be medically necessary, but it still treats them as higher-risk than approved drugs. Pharmacy and veterinary groups have spent years debating how to preserve access while tightening oversight, and FDA last month issued draft GFI #256B addressing compounding under current good manufacturing practice in federally registered facilities, with comments requested by November 27, 2026. In parallel, NABP has been pushing for stronger compounding oversight and more systematic adverse-event reporting. (fda.gov)

Why it matters: For veterinary professionals, this is less about one company’s operational problem and more about the practical fragility of the compounding supply chain. Many clinics rely on compounded drugs for chronic feline, canine, equine, and exotic cases where adherence or dosing precision depends on a customized formulation. A recall of this size can quickly turn into a care-access issue, forcing teams to identify affected lots, contact pet parents, assess whether symptoms could reflect underdosing or overdosing, and decide whether to bridge with an approved product, a different compounded preparation, or supportive monitoring. It also reinforces the need to vet pharmacy partners carefully, document medical necessity, and keep contingency plans for high-dependence compounded therapies. (fda.gov)

There’s also a trust dimension. Wedgewood is one of the most prominent names in veterinary compounding, and its own materials emphasize quality systems, PCAB accreditation, and investment in analytical chemistry capabilities. That background may reassure some practices that the issue was internally detected, but it also raises the stakes because many veterinary teams use the company at scale. The immediate question for clinics is operational: which patients are affected, what alternatives exist, and what level of follow-up is warranted based on the drug, indication, and clinical stability of the animal. (wedgewood.com)

What to watch: Watch for whether FDA classifies the recall by risk level, whether the list of affected products expands, and whether professional groups or pharmacy regulators issue added guidance on monitoring, substitution, and reporting adverse events tied to recalled compounded medications. (fda.gov)